Actinogen Medical Limited (ASX:ACW)

13.5¢

right-arrow Created with Sketch. -0.01 (-6.9%)
MCAP $226.3M
Last trade 16.10pm 26/11/2021 20mins delayed

Latest Announcements

25/11/2021ACWActinogen Medical Limited
25/11/2021ACWActinogen Medical Limited
25/11/2021 Price SensitivePSACWActinogen Medical Limited
25/11/2021 Price SensitivePSACWActinogen Medical Limited
23/11/2021 Price SensitivePSACWActinogen Medical Limited
12,193
MCap
18/11/2021ACWActinogen Medical Limited
18/11/2021ACWActinogen Medical Limited
18/11/2021ACWActinogen Medical Limited

Company Overview

Actinogen Medical Limited is an Australia-based biotechnology company. The Company is engaged in developing treatment for cognitive impairment associated with neurological diseases of raised cortisol levels inside brain cells. The Company's lead drug candidate, Xanamem, has been designed to block the production of cortisol the stress hormone in the brain. Xanamem is a unique inhibitor of the 11β-HSD1 enzyme that achieves target engagement in the central nervous system. It is an oral medication for neurological diseases amenable to its mechanism of lowering cortisol in brain cells. Chronically elevated cortisol is associated with cognitive decline in Alzheimer’s Disease, linked to cognitive impairment and anxiety in Fragile X syndrome, and cognitive impairment in neuropsychiatric diseases. The Company focuses on developing Phase II clinical trial evaluating Xanamem in the treatment of cognitive impairment associated with Alzheimer’s disease.

ACW in the news

Actinogen Medical (ACW) has gained FDA approval to proceed with a clinical…
Biotech company Actinogen Medical (ACW) is granted a Brazilian patent for its…
Actinogen Medical (ACW) enrols its first patient in Part A of a…

Search Previous Announcements